For the latest COVID-19 information, visit


News Center

Latest News


Massey researcher harnessing supercomputers in the race against COVID-19

May 20, 2020


Massey researcher Michael H. Peters, Ph.D., is using powerful supercomputers at NASA’s Ames Research Center in California’s Silicon Valley to investigate the “spike” protein of the novel coronavirus that causes COVID-19.

Through advanced computer simulations, Peters hopes to determine the mechanistic action of the spike protein, which plays an important role in attaching to human cells and infecting the body. He has identified a possible factor that may be able to restrict an important action of this key protein.

“We are trying to more fully understand how this protein functions,” said Peters, who is a member of the Developmental Therapeutics research program at VCU Massey Cancer Center and professor in the Department of Chemical and Life Science Engineering at the VCU College of Engineering. “You have to understand your enemy before launching into battle.”

Peters conducts experimental and theoretical research in the field of protein engineering at VCU College of Engineering. He is working with a former graduate student, Oscar Bastidas (Ph.D.’18), now a postdoctoral research fellow at University of Minnesota’s College of Biological Sciences. They are studying the dynamics of how the spike protein changes between active and inactive states. The protein’s receptor binding domain has an “up” position, in which it can bind to epithelial cell molecules. But in the “down” position, it appears to be incapable of binding, Peters said.

“What is remarkable is that the up domain configuration is molecularly tethered to the main structure of the protein like a tethered balloon. There are two molecular tethers that are stabilized or ‘tied down’ by so-called beta strand structural motifs in the central part of the protein. That is why I have called this virus the ‘It’ virus,” he said, referring to the shape-shifting creature in author Stephen King’s horror tale.

Peters said they mapped the all-atom biomolecular dynamics of the entire spike protein and believe they have discovered a possible molecular “latch” that helps to keep the spike protein down.

Peters is able to access the supercomputers as part of the COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

“The spike protein is a true giant among proteins and difficult to attack without the best computers out there,” he said. “We need to move as fast as possible gathering intelligence and planning attacks.” 

Additionally, Peters is developing a potential COVID-19 treatment for Hoth Therapeutics Inc., a biopharmaceutical company based in New York. VCU has entered into a sponsored research agreement with Hoth for Peters to continue developing and optimizing the possible therapeutic. Hoth, through VCU’s Innovation Gateway, holds an exclusive, long-term license for Peters’ patent for a new molecule. 

Peters has developed a small peptide molecule that demonstrates strong and stable attachment to the spike protein, mimicking the way the virus binds to those surface molecules. If the novel molecule can directly block the initial process of the virus attachment, it could prevent invasion and limit transmission of the virus. He received a VCU COVID-19 Rapid Research Funding Opportunity in May to test the molecule.


Peters joined Hoth’s scientific advisory board in May.

“VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease,” said Robb Knie, CEO of Hoth Therapeutics, in a written statement. “We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic.”

Re-purposed from articles written by Emi Endo, of the VCU College of Engineering.

Editor's Note: This article was updated on July 14, 2020 to reflect ongoing updates to Michael Peters' research.

Written by: VCU College of Engineering

Related News

Community Engagement & Health Equity, COVID-19

Facts & Faith Fridays covers COVID-19, affordable housing and access to fresh food

Get access to new, innovative care

Get access to new, innovative care

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Search clinical trials
Find a provider

Find a provider

Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.

Find a provider